Avastin a Deadly Toxic Cancer Drug with and Astronomical Pricetag.
Avastin, the wonder drug, cuts off tumors’ blood supply. It can cost $100,000 a year, with sales of about $3.5 billion per year. Do we ask how this toxic deadly, not very effective drug is one of the most popular drugs in the USA for the cancer for-profit business? It can but not always extend life by a month or two. They also claim better functioning, but where is the evidence behind that? There is no compelling evidence, yet doctors prescribe this profitable, potentially deadly, debilitating drug anyway. It is a biologic, not chemotherapy but just as deadly.
But don’t worry only 2% of people who take the drug will have a stroke and the really great news only 0.15% will go blind. Even better—not all who have a stroke will die.
In the United States, insurance companies have refused to pay for all or part of the costs of Avastin therapy and reimbursement is also restricted in Canada due to the low benefit-to-cost ratio.
Across clinical studies, Avastin was discontinued in 8% to 22% of patients because of adverse reactions.
Your doctor will not hand you the BLACK BOX WARNING (as seen to the right) and discuss the possibility that this drug can cause blindness, leave you with permanent life-altering adverse side effects or kill you. This is a for-profit business. This is not about curing you. If they wanted to heal you, they would tell you that chemotherapy is toxic and possibly deadly, and you would have a better survival rate if you did not do it.
- Gastrointestinal (GI) perforation
- Serious and sometimes fatal GI perforation occurs at a higher incidence in Avastin-treated patients compared to patients treated with chemotherapy
- The incidence of GI perforation ranged from 0.3% to 3% across clinical studies
- Discontinue Avastin in patients with GI perforation
- Surgery and wound healing complications
- The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in Avastin-treated patients
- Withhold Avastin for at least 28 days prior to elective surgery. Do not administer Avastin for at least 28 days after surgery and until the wound is fully healed
- Discontinue in patients with wound healing complications requiring medical intervention
- Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding, occurred up to 5-fold more frequently in patients receiving Avastin. In clinical studies, the incidence of grade ≥3 hemorrhagic events among patients receiving Avastin ranged from 0.4% to 7%
- Do not administer Avastin to patients with serious hemorrhage or a recent history of hemoptysis (≥1/2 tsp of red blood)
- Discontinue Avastin in patients who develop Grade 3-4 hemorrhage
WARNING: GASTROINTESTINAL PERFORATIONS, SURGERY
AND WOUND HEALING COMPLICATIONS and HEMORRHAGE
See full prescribing information for complete boxed warning. Gastrointestinal Perforations: Discontinue for gastrointestinal
(5.1) Surgery and Wound Healing Complications: Discontinue in
patients who develop wound healing complications that require
medical intervention. Withhold for at least 28 days prior to
elective surgery. Do not administer Avastin for at least 28 days
after surgery and until the wound is fully healed.
(5.2) Hemorrhage: Severe or fatal hemorrhages have occurred. Do not
administer for recent hemoptysis. Discontinue for Grade 3-4